GLENMARK PHARMACEUTICALS USA

Pharmaceutical manufacturing

Filings
33
Clients
1
Total Income
Years Active
2017–2024

Filings

Year Client Period Income Expenses Doc
2024 GLENMARK PHARMACEUTICALS USA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Termination (No Activity)
2024 GLENMARK PHARMACEUTICALS USA 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report (No Activity)
2023 GLENMARK PHARMACEUTICALS USA 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report (No Activity)
2023 GLENMARK PHARMACEUTICALS USA 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report (No Activity)
2023 GLENMARK PHARMACEUTICALS USA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report (No Activity)
2023 GLENMARK PHARMACEUTICALS USA 1st Quarter (Jan 1 - Mar 31)
AMENDED
2023 GLENMARK PHARMACEUTICALS USA 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report (No Activity)
2022 GLENMARK PHARMACEUTICALS USA 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report (No Activity)
2022 GLENMARK PHARMACEUTICALS USA 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Termination
$115,000
2022 GLENMARK PHARMACEUTICALS USA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$136,000
Page 1 of 4  ·  33 filings Next

Clients Represented

ClientFilingsTotal Income
GLENMARK PHARMACEUTICALS USA 33

Lobbyists

NameDisclosed Prior Position
GRANT ERDEL Senator Christopher Bond - Legislative Correspondent Representative Jo Ann Emerson - Administration Assistant Represen…